John Mendlein
From Wikipedia, the free encyclopedia
Dr. John Mendlein is a biotech executive and currently CEO of Adnexus Therapeutics, a Boston, MA based biotech company. He was formerly CEO of Affinium Pharmaceuticals.
Under Dr. Mendlein's leadership, Adnexus was acquired by Bristol Myers Squibbs for roughly US$400M.
[edit] External links
This article about a chief executive from the United States is a stub. You can help Wikipedia by expanding it.
